Clinical Trials | 01 September 2022
Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care
The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.
The NTM-001 Phase I clinical study is expected to be completed by the end of 2022
The tenure of contract will be upto 10 years from date of signing the contract/installation.
Merck’s first microbiology application and training lab in India
Lupin Diagnostics will equip doctors with accurate diagnosis in the patient journey by leveraging innovative technologies
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
Subscribe To Our Newsletter & Stay Updated
